| Abstract: |
| The therapeutic challenge in oncology arises from the intrinsic complexity of the tumor ecosystem, shaped by both intratumoral heterogeneity and dynamic evolutionary processes. This talk presents an integrated framework combining mathematical modeling, biological experiments, and clinical data to dissect these complexities and translate biological insight into clinically actionable strategies.
I begin by examining the role of the tumor microenvironment, with a particular focus on cancer-associated fibroblasts (CAFs) and cell-intrinsic signaling heterogeneity. Our studies, spanning from the role of senescent fibroblasts in melanoma initiation to recent ordinary differential equation (ODE) models of CAF heterogeneity, show how both extrinsic and intrinsic factors drive tumor progression and therapeutic resistance. Using spatial simulations, we further investigate how the spatial organization of resistant cells and fibroblasts shapes treatment response, underscoring the importance of spatially explicit modeling in complex tumor systems.
Building on this foundation, I then shift from understanding resistance mechanisms to managing them through an evolutionary perspective. I will discuss the development of patient-calibrated mathematical models for predicting responses to adaptive therapy. In contrast to conventional maximum tolerated dose (MTD) strategies, which often promote the expansion of resistant clones, our work focuses on evolutionary dosing and the identification of effective dose windows. These approaches aim to preserve a population of treatment-sensitive cells that can suppress resistant populations through competition, thereby delaying competitive release and prolonging tumor control.
Finally, I will highlight ongoing efforts to bridge mathematical theory and clinical translation, including key open questions in adaptive therapy. Collectively, these studies illustrate the power of integrating theoretical, experimental, and clinical approaches to advance a more personalized and evolution-informed cancer treatment strategy. |
|